Ken Hall takes a look at two big-name retirement shares in the FTSE 100 with market-leading positions and track records of ...
The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity, ...
It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...